載入...
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic therapies for this condition. Currently, biol...
Na minha lista:
| 發表在: | Psoriasis (Auckl) |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6120577/ https://ncbi.nlm.nih.gov/pubmed/30214892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S146640 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|